• You are here :
  • Home
  • | Experience
  • | News

Ceri Medical Acquired by Business & Decision Life Sciences


Print | Export as PDF

Send to a colleague

Contact us

Combined companies provide unrivalled capabilities for observational and epidemiological studies across Europe.

Ceri Medical, a specialist epidemiological development services company with over 20 years’ experience in designing, running and reporting epidemiological and observational studies, has announced that it has been acquired by Business & Decision Life Sciences.


Headquartered in Paris, France, Ceri Medical specializes in providing strategic consulting and operational support for non-interventional studies. In the last full year, the turnover of Ceri Medical was over €1.5m and many of the large pharmaceutical companies in France are active clients of Ceri Medical. Services include expertise in study design, adequate implementation and follow-up in order to reach defined objectives, data exploitation, and all the required regulatory reporting for today’s global clinical trials environment.


Commenting on the acquisition, Xavier Gobert, Chief Strategy Officer, Business & Decision Life Sciences, said:

“Business & Decision Life Sciences’ contract research organization is helping our customers to reduce the time and cost of drug development. We are achieving this through the combination of our industry expertise and enabling innovative technologies. With the increasing focus on cost/benefit analyses by government agencies and institutional payers, Ceri Medical’s epidemiological capabilities will further differentiate and enhance our services to help our worldwide customers better understand the burden and causes of health problems in human populations.  Additionally, Ceri Medical’s well-established presence in France will also broaden our existing capabilities in this important market”.

"Business & Decision Life Science is the perfect fit for Ceri Medical” said Dr. Serge Bergal, CEO of Ceri Medical. “Our expertise in running non-interventional studies now has the support platform of a well-respected, biometrics specialist CRO that, through its approach to study conduct, will allow our clients to benefit through greater cost savings”.

Dr. Jean-Marc Nores, Relational Expert of Ceri Medical added, “Business & Decision Life Sciences’ focus on EDC tools that are fully aligned with the needs of running observational studies is a very positive development for our clients”.


With the integration of the two companies, Ceri Medical's management will become part of senior leadership team of the expanded BDLS organisation.


About Ceri Medical

Ceri Medical was founded in 1986 by Drs. Serge Bergal and Jean-Marc Nores and is specialized in epidemiological and observational studies.


For 16 years, Ceri Medical has helped and supported pharmaceutical companies with their diverse studies and projects, including many studies for marketed drugs that have been requested by regulatory authorities.


Ceri Medical provides the full range of services in the management of studies, from protocol writing to study reporting and article publication.  It has built up a very strong network of French Key Opinion Leaders across many therapeutic areas.

More information at http://www.cerimedical.com/.



  • follow us on
  • Twitter
  • Linked In